Drug Profile
Samixogrel
Alternative Names: DDX 30; DTTX 30; DTTX 30SELatest Information Update: 22 Jul 2011
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- Class Antithrombotics
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications; Thrombosis; Unstable angina pectoris
Most Recent Events
- 22 Jul 2011 Discontinued - Phase-II for Thrombosis in Germany (PO)
- 22 Jul 2011 Discontinued - Preclinical for Diabetic complications in Spain (unspecified route)
- 22 Jul 2011 Discontinued - Preclinical for Thrombosis in Canada (unspecified route)